Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
Protein convertase subtilisin kexin type 9 (PCSK-9) inhibitors demonstrated efficacy in cholesterol reduction and in the prevention of cardiovascular events. The investigators will evaluate changes in lipid profile, oxidation markers and subclinical atherosclerosis in patients with familial hypercholesterolemia (FH) during 12 weeks of treatment with a PCSK-9 inhibitor, Evolocumab®.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• diagnosis of FH (clinical and/or genetic)
• eligibility of patients to start a treatment with PCSK-9 according to 2016 ESC guidelines.
Locations
Other Locations
Italy
Matteo Di Minno
RECRUITING
Napoli
Time Frame
Start Date: 2017-12-01
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 25
Treatments
Patients with FH starting a treatment with Evolocumab®
Related Therapeutic Areas
Sponsors
Leads: Federico II University